Premium
Genotype‐guided antiplatelet therapy for acute coronary syndrome percutaneous coronary intervention patients: A new standard of care?
Author(s) -
Ashley Kellan E.,
Hillegass William B.
Publication year - 2021
Publication title -
catheterization and cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 116
eISSN - 1522-726X
pISSN - 1522-1946
DOI - 10.1002/ccd.29659
Subject(s) - medicine , percutaneous coronary intervention , acute coronary syndrome , myocardial infarction , cardiology , conventional pci , population , intensive care medicine , environmental health
Key Points In acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention, ischemic and bleeding outcomes at 1 year can be meaningfully improved with genotype‐guided antiplatelet therapy (GGT). At the population level, GGT appears cost‐effective and perhaps cost‐saving in ST‐elevation myocardial infarction patients only when initiated during the index ACS hospitalization. At the individual patient level, practical clinical and economic factors undercut the feasibility of GGT becoming a new standard of care.